

Sofosbuvir-Containing Regimens in Patients with Renal Disease

HCV TARGET (Renal)

Source: Saxena V, et al. Liver Int. 2016;36:807-16.

Sofosbuvir-Containing Regimens in Patients with Renal Disease

HCV-TARGET Trial: Study Features


HCV-Target and Patients with Renal Disease: Features

- **Design:** Longitudinal, treatment cohort study with sofosbuvir-containing regimens, including patients with renal disease
- **Setting:** 56 centers in US, Germany, and Canada
- **Entry Criteria**
 - Chronic HCV treated with sofosbuvir-containing regimen
 - Age 18 or older
 - Includes patients with baseline renal insufficiency
 - Includes patients with cirrhosis
- **Primary End-Points**
 - Efficacy (SVR12) and safety

Sofosbuvir-Containing Regimens in Patients with Renal Disease

HCV -TARGET


HCV TARGET: SVR12, by Baseline eGFR



Sofosbuvir-Containing Regimens in Patients with Renal Disease

HCV-TARGET Trial: Result

HCV-TARGET Trial: SVR12 Results by Baseline eGFR and Regimen



*eGFR units = mL/min/1.73 m²

Sofosbuvir-Containing Regimens in Patients with Renal Disease HCV-TARGET Trial: Conclusions

Conclusion: “Sustained viral clearance was achieved in 83% of patients with renal impairment (eGFR ≤ 45 ml/min/1.73 m²) treated with sofosbuvir-containing regimens. However, these patients had higher rates of anaemia, worsening renal dysfunction and serious adverse events regardless of use of RBV. Patient with renal impairment require close monitoring and should be treated by providers extensively experienced with SOF-containing regimens.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.